EditorialOriginal Research

Comorbidities, Utilization, and Quality of Care as Predictors of Diabetes Complications

Winston Liaw, Omolola E Adepoju, Carlos G Fuentes, Jiangtao Luo, Bill Glasheen, Ben King, Ioannis Kakadiaris, Todd Prewitt, Pete Womack, Jess Dobbins and LeChauncy Woodard
The Journal of the American Board of Family Medicine January 2026, 39 (1) 157922; DOI: https://doi.org/10.3122/jabfm.2025.250185R1

References

  1. ↵
    1. Ansah J. P.,
    2. Chiu C. T.
    (2023) Projecting the chronic disease burden among the adult population in the United States using a multi-state population model. Front Public Health 10:1082183, doi:10.3389/fpubh.2022.1082183, https://doi.org/10.3389/fpubh.2022.1082183. .
    OpenUrlCrossRefPubMed
  2. ↵
    1. Kaptoge S.,
    2. Seshasai S.,
    3. Sun L..,
    4. et al.
    (2023) Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation. Lancet Diabetes Endocrinol 11(10):731–742. .
    OpenUrlPubMed
  3. ↵
    1. Scollan-Koliopoulos M.,
    2. Bleich D.,
    3. Rapp K. J.,
    4. Wong P.,
    5. Hofmann C. J.,
    6. Raghuwanshi M.
    (2013) Health-Related Quality of Life, Disease Severity, and Anticipated Trajectory of Diabetes. Diabetes Educ 39(1):83–91, doi:10.1177/0145721712467697. .
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Parker E. D.,
    2. Lin J.,
    3. Mahoney T..,
    4. et al.
    (2024) Economic costs of diabetes in the U.S. in 2022. Diabetes Care 47(1):26–43, doi:10.2337/dci23-0085. .
    OpenUrlCrossRefPubMed
  5. ↵
    (11 29, 2023) National Diabetes Statistics Report | Diabetes | CDC. . 2024-5-3. https://www.cdc.gov/diabetes/data/statistics-report/index.html.
  6. ↵
    1. Rowley W. R.,
    2. Bezold C.,
    3. Arikan Y.,
    4. Byrne E.,
    5. Krohe S.
    (2017) Diabetes 2030: Insights from Yesterday, Today, and Future Trends. Popul Health Manag 20(1):6–12, doi:10.1089/pop.2015.0181, https://doi.org/10.1089/pop.2015.0181. .
    OpenUrlCrossRefPubMed
  7. ↵
    1. Stratton I. M.
    (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321(7258):405–412, doi:10.1136/bmj.321.7258.405, pmid:10938048, pmcid:PMC27454. .
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Ravaut M.,
    2. Sadeghi H.,
    3. Leung K. K..,
    4. et al.
    (2021) Predicting adverse outcomes due to diabetes complications with machine learning using administrative health data. Npj Digit Med 4(1):24, doi:10.1038/s41746-021-00394-8, pmid:33580109, pmcid:PMC7881135. .
    OpenUrlCrossRefPubMed
  9. ↵
    1. Parker E. D.,
    2. Lin J.,
    3. Mahoney T..,
    4. et al.
    (2024) Economic Costs of Diabetes in the U.S. in 2022. Diabetes Care 47(1):26–43, doi:10.2337/dci23-0085. .
    OpenUrlCrossRefPubMed
  10. ↵
    1. Antono B.,
    2. Bazemore A.,
    3. Dankwa-Mullan I..,
    4. et al.
    (2021) The State of Primary Care in the United States: A Chartbook of Facts and Statistics (Robert Graham Center; IBM-Watson Health; American Board of Family Medicine & Center for Professionalism & Value in Health Care), https://www.graham-center.org/content/dam/rgc/documents/publications-reports/reports/PrimaryCareChartbook2021.pdf?utm_source=chatgpt.com. . 2025-5-15.
  11. ↵
    1. S L.,
    2. K K.
    (2023) National Hospital Ambulatory Medical Care Survey: 2019 National Summary Tables (National Center for Health Statistics (U.S.)), doi:10.15620/cdc:123251, https://doi.org/10.15620/cdc:123251. .
    OpenUrlCrossRef
  12. ↵
  13. ↵
    1. Zhuo X.,
    2. Zhang P.,
    3. Hoerger T. J.
    (2013) Lifetime Direct Medical Costs of Treating Type 2 Diabetes and Diabetic Complications. Am J Prev Med 45(3):253–261, doi:10.1016/j.amepre.2013.04.017, https://doi.org/10.1016/j.amepre.2013.04.017. .
    OpenUrlCrossRefPubMed
  14. ↵
    1. Young B. A.,
    2. Lin E.,
    3. Von Korff M..,
    4. et al.
    (2008) Diabetes Complications Severity Index and Risk of Mortality, Hospitalization, and Healthcare Utilization. Am J Manag Care 14(1):15–23. .
    OpenUrlPubMedWeb of Science
  15. ↵
    1. Hazel-Fernandez L.,
    2. Li Y.,
    3. Nero D..,
    4. et al.
    (2015) Relationship of diabetes complications severity to healthcare utilization and costs among Medicare Advantage beneficiaries. Am J Manag Care 21(1):e62–70. .
    OpenUrlPubMed
  16. ↵
    1. Schmidt E. M.,
    2. Barnes J.,
    3. Chen C.,
    4. Trafton J.,
    5. Frayne S.,
    6. Harris A. H. S.
    (2019) Patient and Health Care Factors Associated With Long-term Diabetes Complications Among Adults With and Without Mental Health and Substance Use Disorders. JAMA Netw Open 2(9), doi:10.1001/jamanetworkopen.2019.12060, pmid:31553472, pmcid:PMC6763972. .
    OpenUrlCrossRefPubMed
  17. ↵
    1. Farias A. J.,
    2. Wu A. H.,
    3. Porcel J..,
    4. et al.
    (2020) Diabetes-Related Complications and Pancreatic Cancer Incidence in the Multiethnic Cohort. JNCI Cancer Spectr 4(5):pkaa035, doi:10.1093/jncics/pkaa035, pmid:33134820, pmcid:PMC7583154. .
    OpenUrlCrossRefPubMed
  18. ↵
    1. Weng W.,
    2. Liang Y.,
    3. Kimball E.,
    4. Hobbs T.,
    5. Kong S.
    (2018) Trends in comorbidity burden and treatment patterns in type 2 diabetes: Longitudinal data from a US cohort from 2006 to 2014. Diabetes Res Clin Pract 142:345–352, doi:10.1016/j.diabres.2018.05.031. .
    OpenUrlCrossRefPubMed
  19. ↵
    1. Young B. A.,
    2. Lin E.,
    3. Von Korff M..,
    4. et al.
    (2008) Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care 14(1):15–23. .
    OpenUrlPubMedWeb of Science
  20. ↵
    1. Du W.,
    2. Liu P.,
    3. Xu W.
    (2022) Effects of decreasing the out-of-pocket expenses for outpatient care on health-seeking behaviors, health outcomes and medical expenses of people with diabetes: evidence from China. Int J Equity Health 21(1):162, doi:10.1186/s12939-022-01775-5, pmid:36384591, pmcid:PMC9667616. .
    OpenUrlCrossRefPubMed
  21. ↵
    1. Wu C. X.,
    2. Tan W. S.,
    3. Toh M. P. H. S.,
    4. Heng B. H.
    (2012) Stratifying healthcare costs using the Diabetes Complication Severity Index. J Diabetes Complications 26(2):107–112, doi:10.1016/j.jdiacomp.2012.02.004. .
    OpenUrlCrossRefPubMed
  22. ↵
    1. Cochrane Metabolic and Endocrine Disorders Group
    1. Duke S.A.S.,
    2. Colagiuri S.,
    3. Colagiuri R.
    (1 21, 2009) Individual patient education for people with type 2 diabetes mellitus. in Cochrane Database Syst Rev, ed Cochrane Metabolic and Endocrine Disorders Group doi:10.1002/14651858.CD005268.pub2, pmid:19160249, pmcid:PMC6486318. .
    OpenUrlCrossRefPubMed
  23. ↵
    1. Wang S.,
    2. Wang S.,
    3. Wang Y.,
    4. Luan J.
    (2024) Glycemic Control, Weight Management, Cardiovascular Safety, and Cost-Effectiveness of Semaglutide for Patients with Type 2 Diabetes Mellitus: A Rapid Review and Meta-analysis of Real-World Studies. Diabetes Ther 15(2):497–519, doi:10.1007/s13300-023-01520-3, pmid:38175486, pmcid:PMC10838895. .
    OpenUrlCrossRefPubMed
  24. ↵
    1. Nkomazana O.
    1. Egbujie B. A.,
    2. Delobelle P. A.,
    3. Levitt N.,
    4. Puoane T.,
    5. Sanders D.,
    6. Van Wyk B.
    (2018) Role of community health workers in type 2 diabetes mellitus self-management: A scoping review. in PLOS ONE, ed Nkomazana O. 13(6):e0198424, doi:10.1371/journal.pone.0198424, pmid:29856846, pmcid:PMC5983553. .
    OpenUrlCrossRefPubMed
  25. ↵
    1. Baradez C.,
    2. Liska J.,
    3. Brulle-Wohlhueter C.,
    4. Pushkarna D.,
    5. Baxter M.,
    6. Piette J.
    (2022) Brief Digital Solutions in Behavior Change Interventions for Type 2 Diabetes Mellitus: A Literature Review. Diabetes Ther 13(4):635–649, doi:10.1007/s13300-022-01244-w, pmid:35279813, pmcid:PMC8917814. .
    OpenUrlCrossRefPubMed
  26. ↵
    1. Jiang D. H.,
    2. O'Connor P. J.,
    3. Huguet N.,
    4. Golden S. H.,
    5. McCoy R. G.
    (2022) Modernizing Diabetes Care Quality Measures: Analysis examines modernizing diabetes care quality measures. Health Aff (Millwood) 41(7):955–962, doi:10.1377/hlthaff.2022.00233, pmid:35759700, pmcid:PMC9288231. .
    OpenUrlCrossRefPubMed
  27. ↵
    1. Glasheen W. P.,
    2. Renda A.,
    3. Dong Y.
    (2017) Diabetes Complications Severity Index (DCSI)—Update and ICD-10 translation. J Diabetes Complications 31(6):1007–1013, doi:10.1016/j.jdiacomp.2017.02.018. .
    OpenUrlCrossRefPubMed
  28. ↵
    1. Centers for Medicare & Medcaid Services
    (10 24, 2024) Risk Adjustment. . 2024-11-20. https://www.cms.gov/medicare/payment/medicare-advantage-rates-statistics/risk-adjustment.
  29. ↵
    1. Groll D.,
    2. To T.,
    3. Bombardier C.,
    4. Wright J.
    (2005) The development of a comorbidity index with physical function as the outcome. J Clin Epidemiol 58(6):595–602, doi:10.1016/j.jclinepi.2004.10.018. .
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Charlson M. E.,
    2. Pompei P.,
    3. Ales K. L.,
    4. MacKenzie C. R.
    (1987) A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40(5):373–383, doi:10.1016/0021-9681(87)90171-8. .
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. SAS
    SAS 9.4. . 2024-8-20. https://www.sas.com/en_us/home.html.
  32. ↵
    1. Hazel-Fernandez L.,
    2. Li Y.,
    3. Nero D..,
    4. et al.
    (2015) Relationship of diabetes complications severity to healthcare utilization and costs among Medicare Advantage beneficiaries. Am J Manag Care 21(1):e62–70. .
    OpenUrlPubMed
  33. ↵
    1. Davies M. J.,
    2. Aroda V. R.,
    3. Collins B. S..,
    4. et al.
    (2022) Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45(11):2753–2786, doi:10.2337/dci22-0034, pmid:36148880, pmcid:PMC10008140. .
    OpenUrlCrossRefPubMed
  34. ↵
    1. Casalino L. P.,
    2. Nicholson S.,
    3. Gans D. N..,
    4. et al.
    (2009) What Does It Cost Physician Practices To Interact With Health Insurance Plans?: A new way of looking at administrative costs—one key point of comparison in debating public and private health reform approaches. Health Aff (Millwood) 28(Supplement 1):w533–w543, doi:10.1377/hlthaff.28.4.w533, https://doi.org/10.1377/hlthaff.28.4.w533. .
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Blood Pressure Lowering Treatment Trialists' Collaboration
    (2013) Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ 347(oct03 1):f5680–f5680, doi:10.1136/bmj.f5680, pmid:24092942, pmcid:PMC3789583. .
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Uk Prospective Diabetes Study Group
    (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317(7160):703–713, doi:10.1136/bmj.317.7160.703. .
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Centers for Disease Control and Prevention
    United States Diabetes Surveillance System. . 2024-8-2. https://gis.cdc.gov/grasp/diabetes/diabetesatlas-surveillance.html.
  38. ↵
    1. The Diabetes Control and Complications Trial Research Group
    (1990) Diabetes control and complications trial (DCCT): update. Diabetes Care 13(4):427–433, doi:10.2337/diacare.13.4.427. .
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Rodriguez-Gutierrez R.,
    2. McCoy R. G.
    (2019) Measuring What Matters in Diabetes. JAMA 321(19):1865, doi:10.1001/jama.2019.4310, pmid:30985865, pmcid:PMC7332201. .
    OpenUrlCrossRefPubMed
  40. ↵
    1. Clarke P. M.,
    2. Gray A. M.,
    3. Briggs A..,
    4. et al.
    (2004) A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 47(10):1747–1759, doi:10.1007/s00125-004-1527-z, https://doi.org/10.1007/s00125-004-1527-z. .
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    1. Basu S.,
    2. Sussman J. B.,
    3. Berkowitz S. A.,
    4. Hayward R. A.,
    5. Yudkin J. S.
    (2017) Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials. Lancet Diabetes Endocrinol 5(10):788–798, doi:10.1016/S2213-8587(17)30221-8, https://doi.org/10.1016/S2213-8587(17)30221-8. .
    OpenUrlCrossRefPubMed
  42. ↵
    1. Diao J. A.,
    2. Shi I.,
    3. Murthy V. L..,
    4. et al.
    (2024) Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations. JAMA 332(12):989, doi:10.1001/jama.2024.12537, pmid:39073797, pmcid:PMC11287447. .
    OpenUrlCrossRefPubMed
  43. ↵
    1. Mensah G. A.,
    2. Wei G. S.,
    3. Sorlie P. D..,
    4. et al.
    (2017) Decline in Cardiovascular Mortality: Possible Causes and Implications. Circ Res 120(2):366–380, doi:10.1161/CIRCRESAHA.116.309115, https://doi.org/10.1161/CIRCRESAHA.116.309115. .
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords